Biotech: Page

  • A still from a video of three women and two men talking.
    Image attribution tooltip
    Colin Babej / BioPharma Dive/BioPharma Dive
    Image attribution tooltip

    Building a biotech in a downturn: 3 lessons from VCs and startup CEOs

    In a panel discussion hosted by BioPharma Dive, venture capitalists and CEOs discuss how startups can navigate a challenging market as well as possible ripple effects from the new U.S. drug pricing law.

    By , • Nov. 3, 2022
  • A science lab with no workers
    Image attribution tooltip
    Getty Images
    Image attribution tooltip

    Rubius replaces CEO as it cuts more jobs and considers a sale

    The struggling biotech’s CFO and top lawyer are also departing amid a new round of layoffs for a company formed by Flagship Pioneering and once worth nearly $2 billion.

    By Kristin Jensen • Nov. 3, 2022
  • Colorized scanning electron micrograph of a natural killer cell from a human donor. Explore the Trendline➔
    Image attribution tooltip
    National Institutes of Allergy and Infectious Diseases. (2016). "Human natural killer cell" [Micrograph]. Retrieved from Flickr.
    Image attribution tooltip
    Trendline

    Cell therapy

    The continued emergence of CAR-T therapy has fueled research into next-generation approaches and new applications, such as its use in autoimmune diseases or in reprogramming cells inside the body.

    By BioPharma Dive staff
  • A financial graph on an abstract background
    Image attribution tooltip
    Getty Images
    Image attribution tooltip

    Surface Oncology to lay off 20% of staff in restructuring

    In cutting jobs, the biotech joins a lengthening list of drug companies forced to trim their workforce this year. It plans to stop work on an antibody cancer drug to focus resources on two other candidates.

    By • Nov. 2, 2022
  • A grey exterior sign with Alkermes' written on it sits in a bed of flowers outside a glass office building.
    Image attribution tooltip
    Permission granted by Karissa Waddick
    Image attribution tooltip

    Alkermes, continuing transformation, plans to split in two

    The biotech’s transition from drug delivery specialist to maker of novel medicines led to competing neuroscience and oncology divisions. The latter will soon become a separate company.

    By • Nov. 2, 2022
  • A toad hides under a rock
    Image attribution tooltip
    Getty Images
    Image attribution tooltip

    RA Capital backs another startup hunting for a better antidepressant

    Lusaris Therapeutics is launching with $60 million to develop an under-the-tongue form of 5-MeO-DMT, a psychoactive compound found in the glands of the Sonoran Desert toad.

    By Ned Pagliarulo • Nov. 2, 2022
  • A 3D illustration of a ribosome as part of an biological cell constructing a messenger RNA molecule.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip

    CSL bets on mRNA vaccines in deal with Arcturus

    The drugmaker agreed to pay $200 million upfront and potentially billions more to license the technology and knowhow from Arcturus to make preventive shots for COVID-19, influenza and other respiratory infections.  

    By Kristin Jensen • Nov. 2, 2022
  • Portrait of a brown-haired man smiling at the camera.
    Image attribution tooltip
    Permission granted by HI-Bio
    Image attribution tooltip

    Armed with $120M, HI-Bio joins race to develop better autoimmune disease drugs

    HI-Bio, incubated by Arch and holding rights to two drugs from MorphoSys, is one of several recently launched startups to tout a precision medicine approach to treating inflammatory disease.

    By • Nov. 1, 2022
  • An illustration of a herpes simplex virus
    Image attribution tooltip
    Getty Images
    Image attribution tooltip

    Replay launches gene therapy spinout Eudora, putting ‘hub-and-spoke’ plans to work

    The public debut of Eudora comes three months after Replay emerged with $55 million and gene delivery technology it claims can outperform AAV viral vectors.

    By • Oct. 31, 2022
  • Colleagues collaborating in an office
    Image attribution tooltip
    Permission granted by QIAGEN
    Image attribution tooltip
    Sponsored by QIAGEN

    Boost agility and speed in your drug development research

    How flexible API access to integrated 'omics data helps boost agility and speed in drug research.

    Oct. 31, 2022
  • Image attribution tooltip
    Gilead Sciences Inc. / Kite Pharma
    Image attribution tooltip

    Gilead, fueled by latest approval, sees CAR-T sales take off

    After a slow start, Gilead’s CAR-T business is growing fast, enabling it to pull ahead of rival cell therapy developers like Bristol Myers Squibb and J&J.

    By • Oct. 28, 2022
  • Two lab scientists work inside a research facility. A man turns to talk to his colleague, who is seated.
    Image attribution tooltip
    Permission granted by Landmark Bio
    Image attribution tooltip

    An unusual alliance opens a gene and cell therapy hub outside Boston

    Landmark Bio, armed with $75 million and a wide range of backers, is the latest company to emerge with plans to open a “bottleneck” to development of the complex medicines.

    By • Oct. 27, 2022
  • A photo of a Biogen building
    Image attribution tooltip
    Permission granted by Biogen
    Image attribution tooltip

    For Biogen investors, company’s outlook rests on next Alzheimer’s drug

    Analysts pressed the company during its latest earnings presentation for more details about the Alzheimer’s drug it’s developing with Eisai — and how the partners plan to avoid some of the pitfalls experienced with Aduhelm. 

    By • Oct. 25, 2022
  • An illustration of two immune checkpoint proteins binding
    Image attribution tooltip
    Getty Images
    Image attribution tooltip

    With new startup, immunotherapy pioneer Lieping Chen tries to turn ‘cold’ tumors ‘hot’

    Chen, who discovered the cancer-protecting protein PD-L1, will work closely with startup Normunity to find targets that can help the immune system reach ‘cold’ tumors.

    By • Oct. 25, 2022
  • A woman smiles at the camera.
    Image attribution tooltip
    Permission granted by Verge Genomics
    Image attribution tooltip
    Q&A // Emerging biotech

    Verge Genomics’ Alice Zhang on a young biotech founder’s ‘superpower’ and going from target to drug

    “Every struggle that I've had has woven a sense of persistence into my DNA,” said Zhang, in an interview about leading a biotech startup as a young CEO.

    By • Oct. 25, 2022
  • 3D Illustration Concept of Human Respiratory System Lungs Anatomy
    Image attribution tooltip
    Getty Images
    Image attribution tooltip

    Vaxcyte rides investor enthusiasm for early pneumococcal vaccine data

    Encouraging study results for a vaccine with broader coverage than Pfizer’s Prevnar 20 sent Vaxcyte’s valuation soaring and could make the company a potential takeover target.

    By • Oct. 24, 2022
  • Male working in a lab.
    Image attribution tooltip
    Permission granted by Aldevron
    Image attribution tooltip
    Sponsored by Aldevron

    Simplify IP for your gene therapy with OTS backbones, plasmids and enzymes

    Read how IP-simplified products can transform your speed to market without needing to reassess operations midway through to commercialization.

    Oct. 24, 2022
  • A logo of Gilead Sciences
    Image attribution tooltip
    Permission granted by Gilead Sciences
    Image attribution tooltip

    Gilead, working to improve cancer cell therapy, partners with California startup

    Synthetic biology technology developed by the startup, Refuge Biotechnologies, could help Gilead produce safer and more effective CAR-T treatments for certain blood cancers. 

    By Ned Pagliarulo • Oct. 20, 2022
  • Image attribution tooltip
    AbbVie
    Image attribution tooltip

    AbbVie to buy UK biotech DJS for $255M

    The deal gives AbbVie an experimental medicine for idiopathic pulmonary fibrosis, as well as a platform for designing antibody drugs that can target proteins known as GPCRs.

    By Ned Pagliarulo • Oct. 20, 2022
  • A blood sample of HER2 for breast cancer diagnosis.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip

    Zymeworks strikes deal with Jazz as HER2 drug developers adjust their plans

    The high bar set by AstraZeneca and Daiichi Sankyo’s HER2-targeting drug Enhertu appears to have influenced Zymeworks’ decision, while leading to a restructuring at Ambrx Biopharma.

    By Kristin Jensen • Oct. 19, 2022
  • The Nasdaq MarketSite is seen on October 12, 2022 in New York City.
    Image attribution tooltip
    Michael M. Santiago via Getty Images
    Image attribution tooltip

    A startup plans an IPO to give a shelved Lilly drug another shot

    Acrivon Therapeutics is looking to fund a development approach it claims could improve the prospects of a cancer drug Lilly scrapped after testing it in a handful of trials. 

    By • Oct. 19, 2022
  • 3D rendering of T cells attacking a cancer cell.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip
    State of Play

    ‘In vivo’ cell therapy: expanding beyond CAR-T

    At least five startups have emerged with new ways to genetically modify immune cells within the body, an approach that, if successful, could widen the field of CAR-T treatment.

    By • Oct. 18, 2022
  • A paved road snakes through a forest of trees.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip

    Treeline Bio deepens investor roots with fresh funding for cancer drug research

    Led by former Loxo and Novartis executives, Treeline has divulged few details about its research, even as it’s raised nearly half a billion dollars and grown to over 130 employees.

    By • Oct. 17, 2022
  • A photo of a Biogen sign
    Image attribution tooltip
    Permission granted by Biogen
    Image attribution tooltip

    Biogen expects longer wait on ALS drug decision from FDA

    The agency has requested more information about tofersen, a closely watched medicine that Biogen is seeking approval of despite a failed Phase 3 trial. 

    By • Oct. 17, 2022
  • Structure of liposome, phospholipid, micelle, 3d render
    Image attribution tooltip

    Mateusz/Shutterstock.com

    Image attribution tooltip
    Sponsored by Emergent Biosolutions

    The demand for nanoparticles in drug formulation is rising

    Collaborating with an experienced partner, such as a Contract Development & Manufacturing Organization (CDMO), could prove to be invaluable in developing nano-based systems.

    By Kate Silver • Oct. 17, 2022
  • A top-down shot of round aspirin pills in a clear plastic bottle.
    Image attribution tooltip
    Tim Boyle/Getty Images via Getty Images
    Image attribution tooltip

    Covalent drugs take the stage — again — in Atlas Venture’s latest startup

    A decade after Celgene bought the Atlas-backed Avila Therapeutics, the venture firm is building Matchpoint Therapeutics to develop covalent medicines for autoimmune diseases.

    By • Oct. 14, 2022